国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Chinese scholars publish biologics guideline in international journal

By Chen Meiling | chinadaily.com.cn | Updated: 2025-05-07 20:26
Share
Share - WeChat

A Chinese guideline on the use of biologic agents in treating chronic rhinosinusitis with nasal polyps was recently published in the 2025 China Issue of Allergy, one of the most prestigious journals in the global fields of allergology and clinical immunology.

It focuses on China-specific clinical data, systematically standardizing key aspects of biologic treatment, such as patient selection, therapeutic protocols and efficacy evaluation, providing authoritative guidance for clinical practice.

"Emerging biologics that selectively target key cytokines present a promising therapeutic alternative for patients suffering from severe, uncontrollable chronic rhinosinusitis with nasal polyps," according to the guideline.

It's the first time that Chinese scholars have published a guideline-type document in a top-tier international journal in this field, offering valuable Chinese experience for global biologic applications, said Zhang Luo, president of Beijing Tongren Hospital and guest editor of the issue, at a news conference in Beijing on Wednesday.

"In the last two decades, the problems of allergic diseases have been increasing dramatically in the world. Now we are facing 2 billion patients with allergic diseases, so this is a serious threat to humankind in the future," he said.

"In the past, we primarily relied on nasal corticosteroid sprays and oral antihistamines, both of which are chemical-based medications. These treatments have been widely used and can effectively control symptoms. However, since they require frequent administration (often daily), patients may find them inconvenient. Now, with these new biologics, just about three injections over an allergy season can effectively manage symptoms. In terms of both efficacy and duration of effect, they represent an improvement over traditional treatments," Zhang said.

He said these medicines are now available in major hospitals, such as in his hospital. However, since biologics are relatively new, their cost remains high — for example, a single injection may cost around 1,000 to 2,000 yuan ($138-276). "But as their use becomes more widespread, prices are expected to gradually decrease, making them more accessible to a larger number of patients," he added.

The 2025 China Issue of Allergy includes 32 articles focusing on the latest research progress of Chinese scholars in areas such as the link between environmental pollution and asthma pathogenesis, gut microbiota dysbiosis and allergies, as well as the mechanisms underlying drug hypersensitivity.

Cezmi Akdis, editor-in-chief of the journal Allergy, the official journal of the European Academy of Allergy and Clinical Immunology, praised China's contribution to the study of allergy, which has "immensely increased" in the last two decades.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
荆州市| 蒙城县| 泾川县| 麻江县| 上杭县| 黄大仙区| 封开县| 灌云县| 冕宁县| 舒兰市| 丰都县| 淮安市| 峨眉山市| 新巴尔虎右旗| 阜平县| 莒南县| 元谋县| 磐安县| 平果县| 深水埗区| 济阳县| 德阳市| 东城区| 宝清县| 青神县| 达日县| 石景山区| 石台县| 淮阳县| 泾源县| 金平| 长丰县| 伊川县| 湘阴县| 郁南县| 赤水市| 得荣县| 开阳县| 五指山市| 荣昌县| 沾益县|